| ID | 1092 |
| Name of the vaccine | Td-pur |
| Microbe | Bacteria |
| Disease name | Tetanus (Lock Jaw) |
| Name of bacteria | Clostridium tetani |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | From 5 years |
| Description of the vaccine | Combination of tetanus toxoid and diphtheria toxoid. |
| Name of the manufacturer | Novartis vaccine Diagnostics GmbH & Co. KG. |
| Name of the manufacturing country | NA |
| Year of manufacture | 2005 |
| Clinical Phase status | Approved |
| Bacterial strain | An obligate anaerobic bacillus, which is gram positive. |
| Efficacy | NA |
| Vaccine formulation | Whitish, turbid suspension |
| Dosage | Primary Immunisation: Three doses.
Booster: At 10 year intervals. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | Immunisation against tetanus and diphtheria. |
| Export | Marketing Authorisation Holder : Biogenetech Co., Ltd., Thailand |
| Approval | Thailand FDA |
| Adjuvant | Aluminium hydroxide |
| Repurposing | For diphtheria. |
| Side effects of vaccine | Erythema , swelling, pain, induration, itching, myalgia, headache |
| Post vaccination | NA |
| Dose type | Combination (4 doses) |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.moph.go.th/sites/drug/Summary/2C_9_48_Td%20pur.pdf |
| Other name | NA |
| Additional Links | NA
|